Bristol Myers Squibb

Healthcare

Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up

Photo by Victor Golmer via iStock

At the heart of the biotech deal is a relatively new drug technology called PD-1/VEGF bispecific antibodies.

2 min read

(Photo credit: A 4/Flickr)

Healthcare

Bristol Myers Squibb Threatens New Rules Will Hinder Drug Production

2 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.